



Singapore 2025

21-24 September
Grand Copthorne Waterfront Hotel
www.iatdmct2025.org



*program is subject to change

CONGRESS PROGRAM OUTLINE

Saturday 20 September 2025

IATDMCT Council Meeting: 10am – 2.30pm, Paradiso Room, Level 3
Meeting with Scientific Committee and Regional Section Chairs/Co-Chairs: 3pm – 5.30pm, Paradiso Room, Level 3

Sunday 21 September 2025 (SingHealth Academy)

09:00 – 11:00	Workshop 1: Introduction to population pharmacokinetic analyses for TDM data: workshop for beginners By PAGANZ	Workshop 2: Enhancing Review Article Writing with the Latest Tools, Including Generative AI	Workshop 3: Mastering TDM Studies in Infectious Diseases: Key Insights and Example Trials	Industry workshop: (09:00-10:30) HPLC for Beginners: Practical TDM from Sample Analysis to Treatment Decision 1 <i>Delivered by:</i> HITACHI
	Seminar room L1-S1	Seminar room L1-S2	Seminar room L1-S3	Seminar room PSL2
	Chair: A/Prof Jacqueline Hannam, The University of Auckland and A/Prof Hesham Al-Sallami, Qatar University	Chair: Dr Souleiman El Balkhi, INSERM UMR-1248	Chair: Dr Iris Minichmayr, Medical University of Vienna and Prof Jan-Willem Alffenaar, The University of Sydney	
	Presenters: A/Prof Jacqueline Hannam, The University of Auckland and A/Prof Hesham Al-Sallami, Qatar University	Presenters: Dr Souleiman El Balkhi, and A/Prof Marc Labriffe, INSERM UMR-1248	Presenters: Dr Anne-Grete Mårtson, University of Leiden, A/Prof Pieter De Cock, Genth University Hospital, Dr Rekha Pai Mangalore, Monash University Prof Rongsheng Zhao, Peking University Third Hospital and A/Prof Dinh Hoa Vu, Hanoi University of Pharmacy	
11:00 – 11:30	Break			
11:30 – 13:30	WORKSHOP 1 Continue	WORKSHOP 2 Continue		Industry workshop: (11:00-12:30) HPLC for Beginners: Practical TDM from Sample Analysis to Treatment Decision 2 <i>Delivered by:</i> HITACHI
	Seminar room L1-S1	Seminar room L1-S2		Seminar room PSL2
13:30 - 14:30	Lunch			Industry workshop: (13:00 – 14:30) HPLC for Beginners: Practical TDM from Sample Analysis to Treatment Decision 3 <i>Delivered by:</i> HITACHI
				Seminar room PSL2
14:30 – 18:00	Registration desk open @ Grand Copthorne Waterfront Hotel			Grand Ballroom foyer
15:00 – 16:30	Welcome to IATDMCT 2025 Congress			Grand Ballroom
	Welcome to the Congress A/Prof Sophie Stocker, IATDMCT 2025 Co-chair			
	Welcome from Principal sponsor Joana Vögelin, Roche Diagnostics AG 			
	Official opening of congress Prof Jan-Willem Alffenaar, IATDMCT President			
	100. Keynote Address: Real-time monitoring of drugs, metabolites and biomarkers: recent advances in in vivo biosensors Dr Kevin Plaxco, University of California, Santa Barbara			
	Chair: A/Prof Sophie Stocker, IATDMCT 2025 Co-chair			
16:30 – 17:30	IATDMCT 2025 Award Presentations <ul style="list-style-type: none">- Irvin Sunshine Award- Patsalos Award- TDM Journal Award			Grand Ballroom
	Chairs: A/Prof Dario Cattaneo, Humanitas University, Prof Jan-Willem, The University of Sydney and Uwe Christians, University of Colorado			
17:30 – 19:00	Welcome reception Sponsored by: 			Grand Ballroom foyer

06:30	Morning River run or Yoga – free activity			
07:00-16:30	Registration desk open			
07:00 – 07:45	Scientific Committee meeting Analytical	Scientific Committee meeting Anti-Infective Drugs	Scientific Committee meetings Clinical Toxicology & Drug of Abuse	Scientific Committee meetings Pharmacogenetics
	Grand Ballroom I	Waterfront Ballroom I	Waterfront Ballroom II	Waterfront Ballroom III
08:00 – 09:30	Oral presentations 1 TDM in Oncology	Oral presentations 2 Anti-infective drugs	Oral presentations 3 Pharmacometrics	Oral presentations 4 Immunosuppressive drugs & Biomarkers
	Grand Ballroom I	Waterfront Ballroom I	Waterfront Ballroom II	Waterfront Ballroom III
	Chairs: Dr Natansh Modi, University of South Australia and Prof Jennifer Martin, School of Medicine and Public Health, The University of Newcastle	Chairs: Dr Indy Sandaradura, The University of Sydney & NSW Health and Anh Thi Nguyen, The University of Sydney	Chairs: A/Prof Tomoyuki Mizuno, Cincinnati Children's Hospital Medical Center and Dr Ranita Kirubakaran, Seberang Jaya Hospital	Chairs: Prof Klemens Budde, Charité Universitätsmedizin Berlin and Prof Kamisha Johnson-Davis, University of Utah / Arup Laboratories
	200. Feasibility of TDM of 5-flurouracil in tertiary-care cancer centre in western India Prof Preeti Kulkarni, Gahlot Institute of Pharmacy	207. Voriconazole dosing in liver dysfunction: From population models to clinical practice Prof Miao Yan, The Second Xiangya Hospital of Central South University	214. Risk factors for tacrolimus AUC-trough concentrations discrepancies among transplant patients A/Prof Florian Lemaitre, Rennes University Hospital	221. Effects of antimicrobial drugs on microbiome-derived reactivation of mycophenolic acid Prof Anders Asberg, Oslo University Hospital
	201. Pharmacokinetics of Cytarabine in Acute Myeloid Leukemia: A noncompartmental and multivariate analysis Stanislas Maisonneuve, Centre Hospitalo-Universitaire d’Angers	208. Exploring cumulative amikacin exposure to prevent ototoxicity Assist Prof Fumiya Watanabe, Meiji Pharmaceutical University	215. Evaluation of model-based strategies for tacrolimus AUC estimation: Man versus machine study A/Prof Florian Lemaitre, Rennes University Hospital	222. Tacrolimus trough concentration to dose ratio: Peak concentration and trough-exposure relationship Amar Levens, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center
	202. TDM-Guided Imatinib dose adjustment in GIST patients undergoing adjuvant therapy A/Prof Hong Zhou, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	209. Optimising difficult-to-treat gram-negative bacterial infection outcomes with individualised Fosfomycin-based combination therapy Assist Prof Tze-Peng Lim, Singapore General Hospital	216. Machine learning and population pharmacokinetics: A hybrid approach for optimizing vancomycin therapy A/Prof Yan Wang, The Second Affiliated Hospital of Xi’an Jiaotong University	223. Plasma p-cresol sulfate and tacrolimus pharmacokinetic variability in liver transplant recipients Dr Huaijun Zhu, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University
	203. Model-based dose optimisation of Anti-Thymocyte Globulin in Allogeneic stem cell transplantation Elias Biris, University of South Australia	210. DNAzyme-functionalized nanoparticles counteract HMGB1 toxicity, mitigating sepsis liver injury and multi-organ failure MingXuan Xiao, The Second Xiangya Hospital of Central South University	217. Awareness, attitudes, and barriers to clinical utilization of Bayesian dose prediction software Dr Sara Alghanem, College of Pharmacy of Kuwait University	224. RSRC1 hydroxymethylation in circulating cfDNA: A novel epigenetic biomarker for UC diagnosis Dr Huibo Li, Peking University Third Hospital
	204. Bioinformatics analysis of glycolysis-driven drug desistance prognosis in lung adenocarcinoma A/Prof Lei Zhang, Department of Pharmacy, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine	211. Beta-Lactam dosing in critically ill children: predictors for failure of target attainment Stef Schouwenburg, Erasmus University Medical Center	218. Population pharmacokinetics and concentration-QTc Analysis of Bedaquiline in patients with multidrug-resistant tuberculosis Dr Jinmeng Li, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine, Department of Pharmacy	225. Tacrolimus levels compared in PBMCs and whole blood among kidney transplant recipients Prof Xuebin Wang, Shanghai Children's Hospital, School of Medicine, Shanghai Jiao Tong University
	205. Active pharmacovigilance trial integrating pharmacogenetics, TDM, and drug-drug interaction analyses in oncology Dr Bianca Posocco, Cro Aviano, National Cancer Institute, IRCCS	212. Comparative evaluation of machine learning models for predicting vancomycin-associated acute kidney injury Assist Prof Yasuhiro Horita, Nagoya City University, Graduate School of Medical Sciences	219. Model-informed precision dosing of linezolid: a model averaging vs single-model approach Antonia Leonhardt, Department of Clinical Pharmacy, Institute of Pharmacy, University of Hamburg	226. Compensatory dosing of tacrolimus after vomiting in kidney transplantation: A model-based approach Dr Caroline Monchaud, INSERM UMR-1248
	206. Seconds-resolved measurements of the transport of methotrexate into the interstitial fluid Jennifer Marie Gibson, University of California	213. Predictive factors for 30-day-mortality after polymyxinB treatment of carbapenem-resistant Gram-negative bacilli Infections Xuemei Luo, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University	220. Pharmacokinetic-based Bayesian approach to assess medication adherence via therapeutic drug monitoring Dr Xiao-Qin Liu, Shanghai Chest Hospital	227. MPA exposure in renal transplantation and clinical outcomes in early post-transplantation period Prof Smita Pattanaik, Post Graduate Institute of Medical Education and Research Chandigarh
09:30 – 09:45	Comfort break			
09:45 -10:30	228. Keynote Address: Beyond the numbers: Mastering therapeutic drug monitoring and smart alternatives A/Prof Lay Hoon Andrea Kwa, Singapore General Hospital			Grand Ballroom I
	Chair: Dr Jana Stojanova, IATDMCT 2025 Co-chair			
10:30 – 11:00	Morning break with exhibitors			Grand Ballroom foyer

Fuel Your Clinical Research with LC-MS Power!

[Booths 5 & 6 | Book your 1-on-1 consultation session]

[Lunch Workshop | Sep 24 (Wed) | 12:30–1:25 PM]

Advance Your Clinical Research with End-to-End LC-MS Solutions





11:00 -12:30	Symposium 1 Young scientist’s symposium	Symposium 2 Prospective implementation of pharmacogenomics in clinical practice: NGS versus targeted genotyping strategies	Symposium 3 Optimizing TB treatment: Innovations, challenges, and the future of therapeutic drug monitoring	Symposium 4 Simplifying drug assays for low-resource environments
	Grand Ballroom I	Waterfront Ballroom I	Waterfront Ballroom II	Waterfront Ballroom III
	Chairs: Dr Lea Wagmann, Saarland University and Prof HuaLin Cai, The Second Xiangya Hospital of Central South University	Chairs: Prof Jesse Swen, Leiden University Medical Center and Dr Erika Cecchin, Centro di Riferimento Oncologico di Aviano (CR), IRCCS	Chairs: Dr Smita Pattanaik, Post Graduate Institute of Medical Education and Research Chandigarh and Dr Dinh Hoa Vu, Hanoi University of Pharmacy	Chairs: Dr Ofelia Noceti, National Center for Liver Transplantation and Liver Diseases and Assist Prof Tze-Peng Lim, Singapore General Hospital
	229. Leveraging on TDM to fight against antimicrobial resistance Dr Nathalie Grace Sy Chua, Singapore General Hospital	233. Minimising adverse drug reactions and verifying economic legitimacy pharmacogenomics implementation in children (MARVEL-PIC): protocol for a national randomised controlled trial of pharmacogenomics implementation A/Prof Rachel Conyers, Cancer Therapies Group, Murdoch Children's Research Institute	237. Delivery of TB drugs to the infection site: Insights from pathogenesis and immunopathology Prof Catherine Ong, National University of Singapore	241. Setting up a LC-MS/MS assay for a new therapeutic drug - lessons learnt Dr Danijela Kocic, St Vincent’s Hospital
	230. Current situation of mass spectrometry analysis of toxins in clinical toxicology Aline Christin Vollmer, Saarland University	234. Clinical implementation of next generation sequencing derived 18-gene pharmacogenomic panel for personalized drug therapy in a general hospital Prof Yusuke Tanigawara, Keio University	238. How to measure TB drug concentrations in limited resources settings; challenges and opportunities Anh Thi Nguyen, The University of Sydney	242. Pushing the limits: Biomarkers and bioanalytical assays for paediatric patient care in low- and middle-resource settings Dr Paula Schaiquevich, Hospital de Pediatria JP Garrahan
	231. Establishment of TDM service in India Prof Sumith K. Mathew, Believers Hospital	235. Integration of pharmacokinetic, pharmacogenetic and pharmacodynamic data in cancer pain management – the example of oxycodone Prof Andrew Somogy, University of Adelaide	239. Implementing TDM in programmatic TB care Prof Rovina Ruslami, UNPAD	243. Using pharmacokinetics as a surrogate marker for pharmacogenetics to optimize resource allocation Dr Azucena Aldaz, Clinica Universidad De Navarra
	232. The production of reactive metabolites may be one of the main causes of clinical drug-induced liver injury mediated by ALK inhibitors Dr Yicong Bian, First Affiliated Hospital of Soochow University	236. Pharmacogenomics implementation for clinical practice in Korea: Current status and perspectives Prof Yong Soon Cho, Inje University College of Medicine	240. What evidence do we need to get TDM into WHO guidelines Prof Jan-Willem Alffenaar, The University of Sydney	244. Phenotyping of DPD enzyme: A practical approach to make 5-FU chemotherapy safer in resource-limited settings Dr Binu Susan Matthew, Clinical Pharmacology Unit, Christian Medical College



Saving lives through continuous diagnostic monitoring

Pioneering wearable diagnostics:

Advancing real-time drug monitoring

Lunch session

Tuesday 23 September 2025

12:30pm - 1:25pm



12:30 – 14:00	Lunch with exhibitors Sponsored by: <div>Demeter 德米特®</div>			Grand Ballroom foyer
12:30-13:25	Industry workshop: Shaping the future of drug testing & diagnostics: Automation meets mass spectrometry Delivered by: <div>Roche</div>			
	Shaping the future of drug testing & diagnostics: Automation meets mass spectrometry YaYuan Lin, Roche Diagnostics International			
	Pushing the boundaries of clinical mass spectrometry: The future of diagnostics with the Roche cobas® i 601 Prof Pieter Vermeersch, University of Leuven			
	Grand Ballroom I	Waterfront Ballroom III		
14:00 – 15:30	Symposium 5 Immunosuppression and infection: monitoring the myth of Janus	Symposium 6 Towards integration of pharmacogenetics and therapeutic drug monitoring in oncology practice	Symposium 7 Creative solutions for global challenges in fentanyl monitoring and toxicology	Symposium 8 Digital transformation for TDM and clinical toxicology research
	Grand Ballroom I	Waterfront Ballroom I	Waterfront Ballroom II	Waterfront Ballroom III
	Chairs: Prof Birgit Koch, Erasmus MC Rotterdam and Prof Florian Lemaitre, Rennes University Hospital	Chairs: Dr Erika Cecchin, Centro di Riferimento Oncologico di Aviano and Dr Ganessan Kichenadasse, Flinders University	Chairs: Ofelia Noceti, National Center of Liver Transplantation and Liver Diseases and Dr Danijela Kocic, St Vincent’s Hospital	Chairs: Dr Jana Stojanova, St. Vincent's Hospital and A/Prof Ryota Tanaka, Oita University Hospital
	245. Altered pharmacokinetics and pharmacodynamics during infection in the post-transplant period A/Prof Christine Staatz, The University of Queensland	249. Pharmacogenetics and metabolic phenotyping for precision anticancer treatment Prof Nuala Helsby, University of Auckland	253. Setting the scene-A clinical perspective on the opioid epidemic A/Prof Bridin Murnion, St. Vincent's Hospital	257. TDM research in the digital age? Amy Legg, Royal Brisbane and Women's Hospital
	246. Individualized immunosuppressive dosing in transplant patients: how the net state evaluation can help Prof Klemens Budde, Charité Universitätsmedizin Berlin	250. Pharmacogenetically informed therapeutic drug monitoring of 5-Fluorouracil: A Swiss perspective on implementation and clinical experience Prof Carlo Largiader, Institute of Clinical Chemistry; Bern University Hospital; Inselspital	254. Detection and monitoring fentanyl use and misuse in patients presented in emergency room and out-patient substance use clinic Lei Fu, Sunnybrook Health Sciences Centre, University of Toronto	258. Real-World big data insights for advancing therapeutic drug monitoring and clinical toxicology Dr Tomoyuki Yamada, Osaka Medical and Pharmaceutical University Hospital
	247. Use of TDM to improve treatment of nontuberculous mycobacteria in vulnerable populations Dr Joy Gibson, Children's Hospital Los Angeles	251. Implementation of pharmacogenetics guided therapeutic drug monitoring in ethnically diverse communities Prof Stephen Ackland, University of Newcastle	255. Leveraging pharmacogenetics for tailored fentanyl overdose prevention and response Dr Guillaume Drevin, Pathologie, Centre Hospitalier Universitaire d’Angers	259. Model Informed precision dosing of biologics in (hemato)oncology: challenges and opportunities? A/Prof Dirk Jan Moes, Leiden University Medical Center
	248. TDM and dosing adjustments during antiviral (CMV and Covid) infections in the transplant recipients Dr Kristina Nadrah, University Medical Centre, Ljubljana	252. Tamoxigenomics and monitoring of endoxifen levels to tailor tamoxifen prescription in ER positive breast cancer patients Prof Balram Chowbay, National Cancer Centre Singapore	256. Fentanyl use and misuse – forensic cases, laboratory biomarkers Dr Fredric Hellman, Dekalb County Medical Examiner’s Office	260. Leveraging machine learning and decision support dashboard to facilitate precision dosing in pediatric patient care A/Prof Tomoyuki Mizuno, Cincinnati Children's Hospital Medical Center
15:30 – 16:00	Afternoon break with exhibitors			Grand Ballroom foyer
16:00-17:00	Oral presentations 5 Analytical	Oral presentations 6 TDM in Oncology	Oral presentations 7 Toxicology & Environmental health	Oral presentations 8 TDM of Biologics
	Grand Ballroom I	Waterfront Ballroom I	Waterfront Ballroom II	Waterfront Ballroom III
	Chairs: Prof Benedetta Sallustio, The Queen Elizabeth Hospital and Prof Sumith K Mathew, Believers Hospital Kerala	Chairs: Prof Andrew McLachlan, The University of Sydney and A/Prof Ashley Hopkins, Flinders University	Chairs: Dr Penny Colbourne, Alberta Precision Laboratories and Prof Nicolas Venisse, CHU Poitiers	Chairs: Dr Olivier Le Tilly, Université De Tours and Prof Teun van Gelder, Leiden University Medical Center
	261. MS-Based quantification of Gemcitabine in Porcine models: Application to drug-eluting stent development Dr Kelvin Goh, Singapore General Hospital, Division of Pharmacy	266. Therapeutic drug monitoring of Everolimus in cancer patients: A single-centre experience Eugene Tan, College of Medicine and Public Health, Flinders Health and Medical Research Institute, Flinders University and Dr Natansh Deepak Modi, University of South Australia	271. Indoor dust: Indirect approach to characterize human exposure to a pesticide cocktail Eloïse Brillard, Université De Poitiers, CNRS 7267 EBI	275. Risk stratification for relapse after intravenous-to-subcutaneous infliximab switching in inflammatory bowel disease Yannick Hoffert, KU Leuven
	262. Development of a Multi-Triazole UPLC-UV assay in plasma for antifungal TDM Celine Sim, Singapore General Hospital, Division of Pharmacy	267. HDMTX: Risk factors of delayed excretion and related ADR in NHL patients Min Zhang, Department of Pharmacy, University Cancer Hospital, Chongqing	272. LCN2 Promotes liver regeneration in APAP-induced injury via Kupffer Cell Reprogramming Bowen Zhai, The Second Xiangya Hospital of Central South University	276. Model-informed dosage de-escalation of infliximab in patients with inflammatory bowel diseases Assist Prof Erwin Dreesen, KU Leuven

	263. Antibody-based enrichment of Albumin-Cys34 Adducts to monitor drug exposure Laura Boffel, Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University	268. Implementation of TDM guideline-based standardized supportive care improves safety of Methotrexate treatment Prof Rongsheng Zhao, Peking University Third Hospital	273. Cisplatin Interaction with Calmodulin and its impact on MLCK: Implications for neurotoxicity Dr Siming Yuan, The First Affiliated Hospital of USTC	277. A population pharmacokinetic model of bevacizumab in Japanese cancer patients with proteinuria Prof Atsushi Yonezawa, Keio University
	264. Utilizing waste plasma as a sustainable resource in antibiotic TDM assay applications Wen Qi Chiang, Singapore General Hospital, Division of Pharmacy	269. Pharmacogenomic influence on high dose methotrexate pharmacokinetics, outcomes, adverse effects in leukaemia Dr Niveditha K, Kasturba Medical College, Manipal Academy of Higher Education	274. Toxicological investigations of suspected spiking cases in Ghent, Belgium: a prospective study Dr Nick Verougstraete, Ghent University Hospital	278. Assessing the utility of TDM for biologics in inflammatory bowel disease management A/Prof Hong Zhou, Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
	265. Rethinking calibration: A scientific dive into diverse strategies and their efficacy Dr Danijela Kocic, St. Vincent's Hospital	270. Melatonin and Chrono-Modulation affect Gemcitabine Pharmacokinetics and CDA activity (MEGA-CLOCK) Assist/Prof Khushboo Bisht, All India Institute of Medical Sciences, Nagpur; All India Institute of Medical Sciences, Rishikesh	Q&A Panel	279. Personalized infliximab dosing for acute severe Ulcerative Colitis: A multi-center pharmacometrics analysis Yannick Hoffert, KU Leuven
17:00 – 18:30	IATDMCT AGM			Grand Ballroom I
19:00-22:00	Young Scientists social event			Henry International Clark Quay

MassTrak™

Immunosuppressant

Calibrator, Quality Control,

and Internal Standard Sets

MassTRAK

Solutions

MassTRAK

Solutions

Quality Control Low

Quality Control Medium

Quality Control High

0

1

2

3

4

5

6

Waters™

Demeter 德米特

Master core tech,
lead chromatography-MS

Hunan Demeter Instruments Co., Ltd. (generally shortened to “Demeter”) leads the clinical application of chromatography-mass spectrometry with its core patented technologies, pioneering the establishment of a clinical chromatography-mass spectrometry system: such as, the direct blood sample mass spectrometry system, on-site mass spectrometry, high-sensitivity 2D chromatography-mass spectrometry, MLC/FLC automatic 2D liquid chromatography, etc. As an automated chromatography-mass spectrometry R&D, application, and manufacturing enterprise based in China, Demeter aims to lead the advanced clinical chromatography and mass spectrometry industry and expand globally.

Hunan Demeter Instruments Co., Ltd.

Beijing • Changsha • Shanghai • Guangzhou • Shenzhen • Wuhan
Zhengzhou • Nanjing • Chengdu • Xi'an • Shenyang




Official website: <https://www.hndemeter.com>

Service Hotline: +86 4000-176-898 Manager Dong: +86 137-8718-7146


Email: demeter@anax.com

Version No.: CHXC-250702-01

07:00-16:30	Registration desk open				
07:00 – 07:45	Scientific Committee meeting Immunosuppressive	Scientific Committee meeting Pharmacometrics	Scientific Committee meeting TDM of Biologics	Scientific Committee meeting TDM in Oncology	
	Grand Ballroom I	Grand Ballroom II	Waterfront Ballroom I	Waterfront Ballroom II	
08:00 -09:00	Walking poster tour presentations 1: Alternative sampling strategies	Walking poster tour presentations 2: Analytical	Walking poster tour presentations 3: Anti-infective drugs	Walking poster tour presentations 4: Clinical toxicology/ Drugs of misuse	Walking poster tour presentations 5: TDM of Biologics/Other
	Grand Ballroom II				
	Chair: Hanna De Baets, Ghent University	Chair: Prof Tze-Peng Lim, Singapore General Hospital	Chair: Cindy Lau, St Vincent's Hospital Sydney	Chair: Prof Loralie Langman, Mayo Clinic	Chair: A/Prof Christine Staatz, University of Queensland
	W200. Determination of methotrexate polyglutamates (MTXPGs) in VAMS microsamples for monitoring adult adherence Dr Arkadiusz Kocur, The Children's Memorial Health Institute	W210. Performance evaluation of LM1010 in determining the serum concentration of linezolid Dr Naoaki Hashimoto, Department of Infectious Diseases, University of Tsukuba Hospital	W219. Meropenem PK/PD targets in ICU: attainment and factors for non-achievement A/Prof Florian Lemaitre, Rennes University Hospital	W228. The Illicit Fentanyl landscape: Trends, concentrations and co-occurrences Dr Melissa Bennett, Alberta Centre for Toxicology, University of Calgary	W238. Impact of diseases and renal function on serum Levetiracetam concentrations Assist Prof Denpong Patanasethanont, Division of Clinical Pharmacy, Faculty of Pharmaceutical Sciences, Khon Kaen University
	W201. 6β-Hydroxycortisol /cortisol ratio in dried blood spots for CYP3A phenotyping in healthy participants A/Prof Hiromi Shibasaki-Hirano, Tokyo University of Pharmacy and Life Sciences	W211. Simultaneous LC-MS/MS analysis of 35 anti-psychotics in human plasma for clinical research Fionn Quinlan, Waters Corp Clinical Unit	W220. Beyond the limits: Therapeutic drug monitoring-guided high-dose Ceftazidime-Avibactam therapy for brain abscess Dr Nathalie Grace Sy Chua, Singapore General Hospital	W229. Cost comparison standard versus extended N-Acetylcysteine therapy in non-Paracetamol-induced acute liver failure Ezazaya Othman, Hospital Sultan Ismail, Johor Bahru	W239. Weight gain associated with automated vs other insulin delivery methods A/Prof Hesham Al-Sallami, College of Pharmacy, Qatar University
	W202. Validation of Toxicological Test of 135 Drugs in VAMs Using LC-MSMS Wanzhu Zhao, University of Colorado	W212. Enhancing mass spectrometry efficiency: Increasing assay capacity for cost-effective analysis Dr Danijela Kocic, St Vincent's Hospital	W221. Effect of ARC and FN on trough level and clearance of teicoplanin A/Prof Ryota Tanaka, Department of Clinical Pharmacy, Oita University Hospital	W230. The effect of the TGA's labelling requirements on reporting Andrographis adverse reactions Dr Ian Musgrave, University of Adelaide	W240. The rational basis for personalized treatment using concentration guided dosing Prof Nick Holford, University of Auckland
	W203. VAMS is promising method for evaluating the pharmacokinetics of (val)ganciclovir in neonates Dr Arkadiusz Kocur, The Children's Memorial Health Institute	W213. 24/7 fully automated therapeutic drug analysis for research projects by LC/MS/MS Toshikazu Minohata, Shimadzu Corporation	W222. Cycloserine-Induced Neuropsychiatric Toxicity in Multidrug-Resistant Tuberculosis: Association with Peak Plasma Concentration Junjie Cheng, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine	W231. Afatinib activates inflammasome leading to afatinib-induced nephrotoxicity Yuka Sakai, Osaka Medical and Pharmaceutical University	W241. TDM of Erythrocyte Methotrexate Polyglutamates in Rheumatoid arthritis? A prospective study Dr Yi Ma and Prof Rongsheng Zhao, Peking University Third Hospital
	W204. Saliva-based therapeutic drug monitoring of oxazolidinone antibiotics Yuki Inoue, Hokkaido University Hospital	W214. UHPLC-MS/MS analysis of traditional and novel Benzodiazepines in urine Mark Ritchie, Waters Clinical Business Unit	W223. Evaluating Meropenem TDM reliability in OPAT settings: A New sampling strategy Dr Eliza Milliken, Hunter New England Local Health District	W232. Elucidation of the mechanism of lorlatinib-induced liver injury Chihiro Otsubo, Osaka Medical and Pharmacy University	W242. Ellagic acid's potential for treating chemotherapy-induced neuropathy: a therapeutic assessment Krishnalekha Bandyopadhyay JSS College of Pharmacy, Mysuru, JSSAHER
	W205. DBS sampling for TDM during OPAT: qualitative analysis of facilitators and barriers Moska Hassanzai, Erasmus Mc University Medical Center	W215. Evaluating the performance of commercial nitazene immunoassay test strips Dr Marthe Vandeputte, Ghent University	W224. Correlation of plasma pharmacokinetics with hair drug concentrations of Linezolid in MDR-TB Aadil Ahmad Sheikh, Jamia Hamdard	W233. Serum concentration of eltrombopag-acyl glucuronide is associated with eltrombopag-induced liver dysfunction Shun Oda, Department of Pharmaceutical Sciences, Graduate School of Comprehensive Human Sciences, University of Tsukuba	W243. Therapeutic drug monitoring of lacosamide concentration in paediatric population with epilepsy Dr Silvia Joseph, Christian Medical College, Vellore
	W206. Quantification of creatinine as endogenous analyte in qDBS and VAMS microsampling devices Dr Arkadiusz Kocur, The Children's Memorial Health Institute	W216. Towards standardized measurement of free valproic acid concentrations: variability in ultrafiltration protocols Cathérine Van herterycck, Ghent University	W225. Amikacin in critically ill paediatric patients: A pharmacokinetics analysis Chin Chiang Toh, Universiti Kebangsaan Malaysia	W234. Investigating new Prophylactic agents for Vancomycin-induced Nephrotoxicity by using Japanese medical big-data Dr Shungo Imai, Keio University Faculty of Pharmacy	W244. Exploring the place of therapeutic drug monitoring in RNA drugs A/Prof Marc Labriffe, INSERM U1248
	W207. Novel TDM strategy for prediction of pulmonary drug deposition via soft-mist inhaler Dr Daiki Hira, Department of Clinical Pharmacology and Therapeutics, Kyoto University Hospital	W217. Selective and sensitive quantitation of 18 steroids using Thermo Scientific™ Stellar™ MS Dr Jingshu Guo, Thermo Fisher Scientific	W226. Determination of ganciclovir in patients after lung transplantation A/Prof Eva Klapkova, Charles University and University Hospital Motol	W235. The outcome of standard versus extended N-Acetylcysteine therapy on non-paracetamol-related liver injury Wan Farhah Adiba Wan Abd Ghafar, Department of Pharmacy, Hospital Sultan Ismail, Johor Bahru	W245. Population pharmacokinetics and exposure-response analysis of rivaroxaban in patients with atrial fibrillation Nian-Shiuan Lai, National Taiwan University Hospital
	W208. Determination of direct oral anticoagulants (DOACs) in qDBS and VAMS microsampling devices Dr Arkadiusz Kocur, The Children's Memorial Health Institute	W218. Selection of internal standards for quantitation of surufatinib Tiantian Tang, Chongqing University Cancer Hospital	W227. Association between vancomycin renal clearance and sarcopenic conditions in critically ill patients Dr In-Jin Jang, Seoul National University	W236. Innovative therapeutic drug monitoring and pharmacogenetics for Fentanyl management and overdose prevention Dr Ofelia Noceti, National Center for Liver Transplantation and Liver Diseases	W246. Dabigatran trough concentrations: Should we monitor? Dr Shamin Mohd Saffian, Universiti Kebangsaan Malaysia

	W209. Saliva-based therapeutic drug monitoring of Linezolid in multidrug-resistant Tuberculosis patients Anh Thi Nguyen, The University of Sydney		W237. Prolonged urinary detection time of 11-nor-9-carboxy-Δ9-tetrahydrocannabinol in a pregnant occasional cannabis user Dr Siri Amundsen and Dr Linn Pedersen Årnes, University Hospital of North Norway	
09:00 – 09:15	Comfort break			
09:15 – 10:00	300. Keynote Address: Toxic disposition modelling - TDM² Prof Nicholas Buckley, The University of Sydney Sponsored by 			Grand Ballroom I
	Chair: Prof Christophe Stove, IATDMCT President elect			
10:00 – 10:30	Morning break with exhibitors			Grand Ballroom foyer
10:00 – 10:30	Poster presentations: Pharmacogenetics, Pharmacometrics, TDM in Oncology, Immunosuppressive Drugs & Biomarkers			Grand Ballroom II
10:30 – 12:00	Symposium 9 Is there a role of TDM for long-acting formulations?	Symposium 10 Food-drug interaction in oncology: Implications for dosing, toxicity and economics of care	Symposium 11 Neglected tropical diseases: Getting the dose right Sponsored by: 	Symposium 12 Personalised dosing at the bedside: Model selection versus model averaging Sponsored by: 
	Grand Ballroom I	Waterfront Ballroom I	Waterfront Ballroom II	Waterfront Ballroom III
	Chairs: Prof Natella Rakhamnina, The George Washington University and A/Prof Dario Cattaneo, Hunimed University, Pieve Emanuele	Chairs: Dr Vikram Gota, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre and Dr Ganessan Kichenadasse, Flinders University	Chairs: A/Prof Jacqueline Hannam, The University of Auckland and Dr Richard Hoglund, Mahidol Oxford Research Unit, Bangkok	Chairs: A/Prof Iris Minichmayr, Medical University of Vienna and A/Prof Hesham Al-Sallami, College of Pharmacy, Qatar University
	301. TDM of LAI antipsychotics: an example to follow for LAI anti-infectives? Prof Georgios Schoretsantis, The Zucker Hillside Hospital	305. The pharmacological effects of using cabozantinib with a light breakfast: The SKIPPY1 study Amy Rieborn, Leiden University Medical Center	310. Modelling of red blood cell turnover to determine safe dosing strategies for treatment of vivax malaria patients Prof Julie Simpson, The University of Melbourne	315. From big data to better dosing: Optimizing patient-specific PK model selection Dr Jasmine Hughes, InsightRX
	302. PopPK modelling and TDM for individualized dosing of long-acting antiretrovirals Dr Paul Thouelle, Lausanne University Hospital	306. Gastrointestinal environment and drug interactions in cancer patients: Insights from clinical trial data A/Prof Ashley Hopkins, Flinders University	311. In silico modelling of triple artemisinin-based combination therapies to inform dosing in areas with emerging antimalarial drug resistance Meg Tully, The University of Melbourne	316. Does it need a team to win? Model averaging in model-informed precision dosing Prof Sebastian Wicha, University of Hamburg
	303. LAI formulations of anti-infectives in adults A/Prof Ethel Weld, Johns Hopkins University School of Medicine	307. Effect of dietary proteins on the pharmacokinetics and toxicity of 5-fluorouracil Prof Jennifer Martin, School of Medicine and Public Health, The University of Newcastle	312. Dose-optimisation of a novel co-formulated triple combination antimalarial therapy: Artemether-lumefantrine-amodiaquine Prof Joel Tarning, Mahidol Oxford Research Unit	317. Using models in clinical practice – How to get there through retrospective and prospective evaluations Dr Nynke Jager, Radboudumc
	304. Long acting treatment of anti-infectives in paediatrics Prof Natella Rakhamnina, The George Washington University	308. Clinical implications of food–drug interactions with small-molecule kinase inhibitors Prof Frank Jansman, Deventer Hospital and University Groningen	313. Mechanistic pharmacokinetic modelling of primaquine in lactating women and breastfed infants for the radical treatment of maternal P. vivax malaria Dr Thanaporn Wattanakul, Mahidol Oxford Tropical Medicine Research Unit	318. Implementing model-based dosing to improve clinical outcomes: Results of external evaluation of vancomycin popPK models and implementation in a NZ hospital Dr Guangda Ma, The University of Auckland
		309. Food effect on the bioavailability of abiraterone and its implications for dosing and mitigating financial toxicity: Results of a randomized controlled trial Dr Vikram Gota, Advanced Centre for Treatment, Research and Education in Cancer, Tata Memorial Centre	314. Role of TDM in model-based individual predictions for treatment of NTDs in breastfeeding mothers Dr Francis Williams Ojara, Gulu University and The Infectious Diseases Institute Kampala	
12:00 – 13:30	Lunch with exhibitors			Grand Ballroom Foyer
12:00 – 13:30	Poster presentations: Pharmacogenetics, Pharmacometrics, TDM in Oncology, Immunosuppressive Drugs & Biomarkers			Grand Ballroom II

12:30-13:25	Industry workshop: Advancing standardization in therapeutic drug monitoring: From metrology concepts to industry solutions Delivered by: 	Industry workshop: Pioneering wearable diagnostics: Advancing real-time drug monitoring Delivered by: 		
	ISD standardization - from early challenges towards a solution Dr Christoph Seger, Labordiagnostic St. Gallen West	Dr Marsilea Harrison (née Booth), Nutromics		
	Metrology in TDM: from academic concepts to IVD-industry support Dr Judith Taibon, Roche Diagnostics			
	Grand Ballroom I	Waterfront Ballroom I		
13:30 – 15:00	Oral presentations 9 Anti-infective drugs	Oral presentations 10 Immunosuppressants	Oral presentations 11 Pharmacogenetics	Oral presentations 12 Clinical toxicology/ Drugs of misuse
	Grand Ballroom I	Waterfront Ballroom I	Waterfront Ballroom II	Waterfront Ballroom III
	Chairs: Dr Nathalie Grace Sy Chua, Singapore General Hospital and A/Prof Pieter De Cock, Ghent University Hospital	Chairs: Fay Burrows, St Vincent’s Hospital and Dr Tee Wee, Company Testing	Chairs: Dr Jan Gerard Maring, Isala Hospital Zwolle and Prof Vincent Haufroid, Cliniques Universitaires Saint-Luc, UCLouvain	Chairs: Prof Nicholas Buckley, The University of Sydney and Dr Melissa Bennett, Alberta Centre for Toxicology, University of Calgary
	319. Predicting ciprofloxacin target non-attainment in critically ill patients with two machine-learning models Andre Wieringa, Isala Hospital	326. Lipopolysaccharide-linked endotoxemia correlates with cyclosporine A exposure in transplant patients A/Prof Roland Lawson, INSERM-U1248 unit	333. An End-to-end bioinformatics solution to support next generation sequencing based pharmacogenetic testing Dr David Yu Yuan, European Nucleotide Archive, European Bioinformatics Institute, European Molecular Biology Laboratory	340. Xylazine positivity trends in drug screens at a large academic medical center A/ Prof Carmen Gherasim, University of Michigan
	320. Beta-lactams therapeutic drug monitoring in intensive care patients: a prospective, comparative study Dr Romain Guilhaumou, Pharmacologie Clinique Et Pharmacovigilance, Aphm	327. Exploring gut microbiota as novel biomarkers for Azathioprine therapeutic drug monitoring Dr Shuai Song, The First Affiliated Hospital of Anhui Medical University	334. Clinical integration of pre-emptive DPYD genotype testing services in a tertiary hospital Deirdre Landsberg, University of South Australia	341. Findings of urine drug screening in the US South region 2020- 2024 A/Prof Jing Cao, University of Texas Southwestern Medical Center
	321. Point-of-care therapeutic drug monitoring of Levofloxacin using saliva in multidrug-resistant Tuberculosis patients Anh Thi Nguyen, The University of Sydney	328. Capillary dried blood spot sampling for Tacrolimus and Creatinine monitoring at home Hanna De Baets, Ghent University	335. Unravelling pharmacogenetic risks in cardiovascular drug safety: Four-years study insights Dr Livija Šimičević, School of Medicine, University of Zagreb	342. Metabolic toll of atypical antipsychotics: AGEs accumulation, mitochondrial dysfunction and cognitive decline Prof Hualin Cai, The Second Xiangya Hospital of Central South University
	322. Levofloxacin: how choosing the right dose in osteoarticular infections? Assist Prof Marie-Clémence Verdier, Rennes University Hospital	329. Extracellular vesicles as a liquid biopsy to characterize variability in medicine exposure Prof Andrew Rowland, Flinders University	336. Pharmacogenetics of brivaracetam: CYP2C9 and CYP2C19 variants impact on TDM real-life data Assist Prof Lana Ganoci, University Hospital Centre Zagreb	343. In vitro biotransformation of six compounds derived from the stimulant prolintane Dr Lea Wagmann, Saarland University
	323. External evaluation of population pharmacokinetic models of vancomycin in neonates Dr Erin Chung, The Hospital for Sick Children	330. Pharmacodynamic biomarker evaluation in renal transplant recipients with/without anti-thymocyte globulin induction Ritika Panwar, Pigmer, Chandigarh	337. MiRNA expressions and DPYD polymorphisms in colorectal cancer patients treated with 5-fluorouracil Assist Prof Phatchariya Phannasil, Institute of Molecular Biosciences, Mahidol University	344. Magnesium Isoglycyrrhizinate alleviates crizotinib-induced liver injury by inhibiting ferroptosis via FOXO3/LPCAT3 pathways Zhiyu Hu, Central South University, Changsha, China
	324. Prophylactic Posaconazole in preventing Invasive fungal diseases in leukemia and BMT patients Dr Serin C S, Christian Medical College, Vellore	331. Feasibility of salivary mycophenolic acid for therapeutic monitoring in renal transplant patients Sheetal Singh, Department of Pharmacology	338. Pharmacogenetics for mavacamten treatment individualization in patients with obstructive hypertrophic cardiomyopathy Dr Sylvie Quaranta, Laboratoire de Biologie Moléculaire GEnOPé, CHU Timone, AP-HM, Marseille	345. Phosphatidylethanol: detecting alcohol in general population and transplant patients A/Prof Xin Yi, Houston Methodist Hospital
	325. Impact of augmented renal clearance on vancomycin pharmacokinetics in paediatric patients Dr Jian Lynn Lee, Department of Pharmacy, Tunku Azizah Hospital, Ministry of Health Malaysia	332. Blood and plasma tacrolimus concentrations and gestational outcomes in pregnant patients Prof Benedetta Sallustio, The Queen Elizabeth Hospital	339. Association of TLR4 rs11536889 Polymorphism with increased risk of tuberculosis in Thai Prin Chaiyakit, Faculty of Medicine, Srinakharinwirot University, Bangkok	346. In-silico DrugBank® database: does CFM-ID-4.0 outperform CFM-ID-2.0 at generating clinical toxicology databases? Dr Emmanuel Bourgogne, Laboratoire De Toxicologie, Pharmacie, Faculté De Santé, Université Paris Cité, Paris, France

15:00 – 15:30	Afternoon break with exhibitors				Grand Ballroom foyer
15:00 – 15:30	Poster presentations: Pharmacogenetics, Pharmacometrics, TDM in Oncology, Immunosuppressive Drugs & Biomarkers				Grand Ballroom II
15:30 – 17:00	Symposium 13 Improving dosing for renally eliminated medicines Sponsored by: 	Symposium 14 Target concentrations, time to reach target, days in target: Therapeutic target parameters	Symposium 15 Invisible inheritance: Maternal exposures and the lifelong health of the next generation	Symposium 16 New psychoactive substances: New drugs, new challenges	
	Grand Ballroom I	Waterfront Ballroom I	Waterfront Ballroom II	Waterfront Ballroom III	
	Chairs: Austin Tan, National University of Singapore and Dr Shaun Kumar, Parexel International, Melbourne	Chairs: A/Prof Sophie Stocker, The University of Sydney and Prof Rovina Ruslami, Faculty of medicine, University Padjadjaran	Chairs: Dr Souleiman El Balkhi, INSERM UMR-1248 and Eloïse Brillard, Université De Poitiers	Chairs: Eric Franssen, OLVG and Prof Christophe Stove, Ghent University	
	347. How to predict renal function from premature neonates to adults Dr Conor O’Hanlon, University of Auckland and Roche Informatics, F. Hoffmann-La Roche AG	352. The impact of inter-individual variation of anti-infective drug exposure and delay in achieving the target concentration on clinical outcome Dr Lee-Lee Low, Hospital Sultanah Bahiyah	356. Mechanisms and implications of maternal-fetal exposure to drugs and environmental toxins Dr Laure Ponthier, Universitary Hospital	360. Pharmacological characterization and activity-based detection of emerging new synthetic opioids Dr Marthe Vandeputte, Ghent University	
	348. A physiological approach to renal clearance informed by renal function Prof Nick Holford, University of Auckland	353. Use of dose optimization programs in achieving target anti-infective drug concentrations early and maintaining it for the duration of anti-infective drug treatment Anne-Grete Märston, University of Leiden	357. Human studies on prenatal exposures: Evidence, trends, and advances Dr Melissa Bennett, Alberta Centre for Toxicology, University of Calgary	361. A snapshot on last generation cathinones in Italy: kinetics, metabolism, acute and fatal intoxications Dr Simona Pichini, National Centre on Addiction and Doping, National Institute Of Health	
	349. Pharmacokinetics during haemodialysis and hemodiafiltration, application to amikacin Dr Laila Nassar, Rambam Health Care Campus, Haifa	354. Strategies to improve therapeutic target attainment for anti-infectives: Leveraging advanced tools and technologies Brigit Koch, Erasmus MC	358. Innovative approaches for maternal-child health assessment: Technological and methodological advances Prof Franck Saint-Marcoux, University Hospital Laboratory INSERM UMR-1248	362. Metabolism and pharmacokinetics of new psychoactive substances, with a focus on synthetic cannabinoids & psychedelics Ziteng Wang, Department of Pharmacology, National University of Singapore	
	350. Disposition of colistin in critically ill patients on sustained low-efficiency dialysis: a population pharmacokinetic study and Monte Carlo simulations Dominika Fuhs, Monash University	355. A randomized controlled trial of therapeutic monitoring-based dosing strategy versus standard dosing strategy of sunitinib in metastatic renal cell carcinoma Vikram Gota, Advanced Centre for Treatment Research and Education in Cancer, Tata Memorial Centre	359. Evolving chemical risk assessment in maternal-child health Dr Souleiman El Balkhi, INSERM UMR-1248		
	351. Model-informed precision dosing of anti-infective drugs in paediatrics A/Prof Xiao Zhu, Fudan University				
18:00	Coaches depart Grand Copthorne Waterfront Hotel				
18:30 -23:00	Congress dinner				Jumbo Seafood East Coast
21:30&23:00	Coaches depart from Jumbo Seafood East Coast to Grand Copthorne Waterfront Hotel				



150

YEARS





ANNIVERSARY

Saving time saves lives

Designed for labs that value both clinical excellence and operational speed in therapeutic drug monitoring



07:00-15:00	Registration desk open				
07:00 – 07:45	Scientific Committee meeting Toxicology & Environmental Health	Scientific Committee meeting Young Scientists	Scientific Committee meeting Communications	Section meeting European Regional section	
	Grand Ballroom I	Waterfront Ballroom I	Waterfront Ballroom II	Waterfront Ballroom III	
08:00 – 09:00	Walking poster tour presentations 6: Immunosuppressive drugs & Biomarkers	Walking poster tour presentations 7: Pharmacogenetics	Walking poster tour presentations 8: Pharmacometrics	Walking poster tour presentations 9: TDM in Oncology	Walking poster tour presentations 10: Toxicology & Environmental health
	Grand Ballroom II				
	Chair: Prof Andrew Rowland, Flinders University	Chair: A/Prof Jessica Cusato, University of Turin	Chair: Dr Joy Gibson, Children's Hospital Los Angeles	Chair: Dr Amar Levens, Leiden University Medical Center	Chair: Dr David Kinniburgh, ACFT, University of Calgary
	W300. Bioenergetic biomarkers in First-episode bipolar disorders: Linking mitochondrial dysfunction with cognitive decline Dr Yue Shen, The Second Xiangya Hospital of Central South University	W307. Genotype-guided dosing of aripiprazole in Chinese adolescents with psychiatric disorders Dr Li Fan, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine	W315. Drug absorption in pulmonary arterial hypertension patients, one sampling time fits all? Assist Prof Paweł K. Kunicki, Department of Drug Chemistry, Pharmaceutical and Biomedical Analysis, Medical University of Warsaw, Warsaw, Poland	W325. A nonparametric population pharmacokinetic model of selumetinib administered to pediatric neurofibromatosis-I patients Dr Zoltan Kollo, Department of Laboratory Medicine, Semmelweis University	W333. Cost-Effectiveness of TDM and personalized interventions in psychiatric care: A comprehensive review Assit Prof Karunrat Tewthanom, Silpakorn University
	W301. Gut microbiota characteristics of Tacrolimus-induced DILI in renal transplant patients Dr Dongke Yu, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital	W308. Clinical validation of a DPD deficiency assay solution Toshikazu Minohata, Shimadzu Corporation	W316. Simulation-driven pharmacometric modeling for bioequivalence using partial AUC in pediatric transplants Prof Catherine Sherwin, Internal Medicine, UWA Medical School, The University of Western Australia	W326. The toxicities of regorafenib are correlated with M5 trough concentration Yukitaka Shibata, Department of Pharmacy, National Cancer Center Hospital	W334. Trace analysis of Alpha-Amanitin in human urine: Implications for poisoning detection Karina Izdebska, Bioanalytic
	W302. Continuous subcutaneous ketamine infusion induces tacrolimus and sirolimus clearance: a case report Dr Jana Stojanova, St Vincent's Hospital Sydney	W309. CYP2C19 genotype-guided voriconazole dosing increases target range attainment and reduces toxicity Dr Yoshiki Katada, Kyoto University Hospital	W317. Leveraging deep Q-networks for starting dose optimization: Case study of Infliximab Dr Kei Irie, Cincinnati Children's Hospital Medical Center	W327. Impact of cancer cachexia progression on OATP1B activity: Quantitative analysis using coproporphyrin-I Takahiro Sumimoto, Oita University Hospital	W335. Boerhavia diffusa extract exhibits monoamine oxidase inhibition but lacks neuroprotective effects Prof Vanessa Steenkamp, University of Pretoria
	W303. Population pharmacokinetics and limited sampling strategies for mycophenolic acid after liver transplantation A/Prof Jiake He, The Second Affiliated Hospital of Nanchang University	W310. Establishment of a novel method to assess CYP1A2 activity using melatonin clearance Dr Akitomo Yokokawa, Tokyo University of Pharmacy and Life Sciences, School of Pharmacy	W318. Pharmacokinetic-pharmacodynamic modeling of Infliximab in children and young adults with Crohn’s disease Wen Rui Tan, Cincinnati Children's Hospital Medical Center	W328. Relationship between osimertinib concentration and toxicity: preliminary assessment in a prospective study Reiko Ando Makihara, Department of Pharmacy, National Cancer Center Hospital	W336. Establishment and safety assessments of micro/nanoplastic libraries 5: Focus on Polyvinyl Chloride Prof Yasuo Tsutsumi, Graduate School of Pharmaceutical Sciences, Osaka University
	W304. Population pharmacokinetics and limited sampling strategies for mycophenolic acid after renal transplantation A/Prof Jiake He, The Second Affiliated Hospital of Nanchang University	W311. The correlation between TDM and CYP2C19 polymorphisms in Voriconazole using Dr Lixian Li, Chongqing University Cancer Hospital	W319. Smart dosing: A line Chatbot revolutionizing initial Vancomycin therapy in Thailand Tippawan Wongwian, Queen Savang Vadhana Memorial Hospital	W329. Plasma concentrations of imatinib in elderly patients with gastrointestinal stromal tumor Takuma Suzuki, Department of Pharmacy, National Cancer Center Hospital	W337. Profiles of bacterial communities and antibiotic resistance genes in the Lahasa River Dr Lv Yayao, Tianjin First Center Hospital
	W305. Significance of time in therapeutic range of Tacrolimus in acute GVHD Prophylaxis Dr Naoki Yoshikawa, Department of Pharmacy, University of Miyazaki Hospital	W312. Personalized Tacrolimus dosing strategies in kidney transplantation optimizing dosing through pharmacogenomics Yi-Jen Huang, National Taiwan University Hospital	W320. MIPD performance assessment and model re-evaluation in children and adults Dr Jordan Brooks, InsightRX	W330. Association of initial drug concentrations with age and sex in cancer therapy Keisuke Ikegami, Keio University Faculty of Pharmacy	
	W306. Continuous quality improvement in immunosuppressant testing: be cautious of clotting samples Dr Meng Wang, Vancouver Coastal Health	W313. Genotype informed Bayesian dosing of tacrolimus in children undergoing solid organ transplantation Dhrita Khatri, Murdoch Children's Research Institute	W321. Exposure – response relationship of adalimumab in Chinese patients with ankylosing spondylitis Dr Xiaoliang Ding, The First Affiliated Hospital of Soochow University	W331. Busulfan therapeutic drug monitoring in allogeneic HSCT patients in Singapore Li Jiao Sin, Singapore General Hospital	
		W314. Pharmacogenetics and pharmacokinetics as useful tools for posaconazole personalization in leukemia patients A/Prof Jessica Cusato, Laboratory of Clinical Pharmacology, Department of Medical Sciences, University of Turin	W322. Development and visualization of a generalizable pharmacokinetics model Kanoko Okuba, The University of Osaka	W332. Therapeutic drug monitoring for early dose personalization of Sunitinib in mRCC Dr Eleonora Cecchin, Centro Di Riferimento Oncologico, Aviano	
			W323. Application of a population model for procalcitonin in adults in intensive care A/Prof Jacqueline Hannam, The University of Auckland		
			W324. Population pharmacokinetics of Rifampicin: Supporting model-assisted TDM in tuberculosis treatment Yuan Pétermann, CHUV		

09:00 – 09:15	Comfort break				
09:15 – 10:00	400. Keynote Address: Personalised medicine of immunosuppressants Xiaoman (Alexis) Liu, The First Affiliated Hospital, Sun Yat-Sen University				Grand Ballroom I
	Chair: Prof Teun Van Gelder, Leiden University Medical Center				
10:00 – 10:30	Morning break with exhibitors				Grand Ballroom Foyer
10:00 – 10:30	Poster presentations: Analytical, Anti-Infective Drugs, Clinical Toxicology & Drugs of Misuse, TDM of Biologics and Other				Grand Ballroom II
10:30 – 12:00	Symposium 17 Dangerous liaisons: an interactive navigation into the antifungals DDI risk	Symposium 18 Precision dosing and safety in psychopharmacology: New insights and innovations	Symposium 19 Model informed precision dosing of biologics: new modalities and pediatrics	Symposium 20 The prediction, prevention and management of drug toxicity	
	Grand Ballroom I	Waterfront Ballroom I	Waterfront Ballroom II	Waterfront Ballroom III	
	Chairs: A/Prof Florian Lemaitre, Rennes University Hospital, INSERM and Dr Rekha Pai Mangalore, Monash University	Chairs: Bram Dierckx, Department of Hospital Pharmacy, Erasmus University Medical Center and Prof Christophe Stove, Ghent University	Chairs: A/Prof Dirk Jan Moes, Leiden University Medical Center, A/Prof Erwin Dreesen, KU Leuven and A/Prof Iris Minichmayr, Medical University of Vienna	Chairs: Prof Miao Yan, The Second Xiangya Hospital of Central South University and Jan-Willem Alffenaar, The University of Sydney	
401. The usual suspects: the classic DDI with antifungal drugs Andre Wieringa, Isala Hospitals, Zwolle	404. Capillary Olanzapine sampling method validation study (COSMOS) / towards precision dosing of Olanzapine in anorexia nervosa patients (TORPEDO)	410. Clinical pharmacology considerations of biologics: fundamentals & principles Prof Donald Mager, University at Buffalo	413. Competency-Based Training for TDM Pharmacists: A National Framework from China Prof Liyan Miao, The First Affiliated Hospital of Soochow University		
	405. Population pharmacokinetics of clozapine in schizophrenia patients: sex differences and impact of fluvoxamine coadministration Jiayi Liang, Erasmus University Medical Center				
	402. Lost in translation: a presentation on some controversial DDI examples Fay Burrows, Pharmacy Department, St. Vincent's Hospital			406. Clinical pharmacokinetics of antipsychotics in pediatric populations: a scoping review focusing on dosing regimen	
407. Evaluating Lithium safety in youth with bipolar disorder: Insights from a comprehensive PK/PD analysis of the CoLT1 study Lisa T Ringeling, Erasmus University Medical Center					
	403. Deep impact: the role of inflammation and genetics on antifungal DDI Haifa Lyster, Royal Brompton & and Harefield Hospitals	408. Comparing saliva and plasma for clozapine therapeutic drug monitoring Dr Jimmy Lee, North Region, Institute of Mental Health, Singapore	412. From struggle to success: Real-world pediatric model-informed precision dosing of biological drugs in stem cell transplantation Dr Kana Mizuno, Cincinnati Children's Hospital Medical Center and University of Cincinnati College of Medicine	415. The high-risk factors and potential mechanisms of hepatotoxicity of voriconazole A/Prof Taotao Wang, The First Affiliated Hospital of Xi'an Jiaotong University	
		409. An international adult guideline for making Clozapine Titration safer by using six ancestry-based personalized dosing Titrations, CRP, and Clozapine levels A/Prof Georgios Schoretsanitis, The Zucker Hillside Hospital	Panel discussion	416. AI-driven clinical prediction and management of antineoplastic drugs' toxicity: From methotrexate chemotherapy to novel therapies Dr Zaiwei Song, Peking University Third Hospital	
12:00 –13:30	Lunch with exhibitors				Grand Ballroom Foyer
12:00-13:30	Poster presentations: Alternative Sampling Strategies, Analytical, Anti-Infective Drugs, Clinical Toxicology & Drugs of Misuse, TDM of Biologics and Other				Grand Ballroom II
12:30-13:25	Industry workshop: Donor-derived cell-free DNA for personalized immunosuppression in transplantation Delivered by: 	Industry workshop: Quantitative and simultaneous plasma drug analysis with LC-MS/MS for therapeutic drug monitoring Delivered by: 	Industry workshop: TDM by LC/MS: From single to multiplex and expansion to novel drugs Delivered by: 	Industry workshop: Advance your clinical research with robust, end-to-end LC-MS solutions Delivered by: 	
	Michael Oellerich, MD, Hon MD, University Medical Centre Goettingen	A/Prof Masamitsu Maekawa Department of Pharmaceutical Sciences, Tohoku University Hospital	Fionn Quinlan, Waters APAC Clinical BU	Dr Jingshu Guo, Thermo Fisher Scientific	
	Grand Ballroom I	Waterfront Ballroom I	Waterfront Ballroom II	Waterfront Ballroom III	

13:30 – 15:00	Oral presentations 13 Anti-infective drugs	Oral presentations 14 TDM in Oncology	Oral presentations 15 Pharmacometrics	Oral presentations 16 Alternative sampling strategies	
	Grand Ballroom I	Waterfront Ballroom I	Waterfront Ballroom II	Waterfront Ballroom III	
	Chairs: Andre Wieringa, Isala Hospital and Dr Anne Grete Märtson, Leiden University	Chairs: Prof Carlo Largiader, Institute of Clinical Chemistry, Bern University Hospital, Inselspital and Prof Stephen Ackland, The University of Newcastle	Chairs: Prof Catherine Sherwin, The University of Western Australia and Meg Tully, The University of Melbourne	Chairs: Wanzhu Zhao, ic42 Clinical Research and Development and Moska Hassanzai, Erasmus Mc University Medical Center	
	417. Well-validated models adequately describe vancomycin pharmacokinetics in patients with acute kidney injury Dr Jasmine Hughes, In sightrx	424. Relationship between pharmacokinetics, pharmacogenetics and adverse events in women treated with tamoxifen Dr Fabienne Thomas-Jean, IUCT-Oncopole Claudius Regaud	431. A joint target-mediated drug disposition/time-to-event model of ramucirumab in gastric cancer Dr Olivier Le Tilly, Université De Tours	438. Comparative evaluation of approaches to convert microsampled capillary blood-based to plasma-based results Laura Boffel, Laboratory of Toxicology, Department of Bioanalysis, Faculty of Pharmaceutical Sciences, Ghent University	
	418. AntibioMIC: a dynamic WebApp helping clinicians interpret antibiotic concentrations for drug monitoring Dr Emmanuel Bourgogne, Laboratoire De Toxicologie, Pharmacie, Faculté De Santé, Université Paris Cité	425. Optimizing Busulfan exposure in Chinese pediatric patients undergoing allogeneic hematopoietic cell transplantation A/Prof Chenrong Huang, The First Affiliated Hospital of Soochow University	432. Model-based precision dosing and non-adherence remediation of isoniazid in Chinese tuberculosis patients Junjie Cheng, Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine	439. Does microsampling enhance preanalytical stability of uracil in dihydropyrimidine dehydrogenase (DPD) phenotyping? Kevin Vandenbroucke, Ghent University	
	419. Mechanistic PBPK modeling predicts population-specific Voriconazole-Tofacitinib interaction risks Dr Shasha Jin, Department of Pharmacy, Ren Ji Hospital, Shanghai Jiao Tong University School of Medicine	426. Clinical validation of capillary microsampling for Venetoclax pharmacokinetic monitoring and home-based self-sampling Dr Amar Levens, Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden	433. Intravenous cefuroxime target attainment in neonates and infants: pooled population pharmacokinetic study Stef Schouwenburg, Erasmus University Medical Center	440. Reducing healthcare’s carbon footprint: Environmental benefits of transporting microsamples vs. frozen plasma Janice Johnstone, The University of Newcastle	
	420. Levofloxacin in osteoarticular infections: could we determine a therapeutic range? Assist Prof Marie-Clémence Verdier, Rennes University Hospital	427. Real-world pharmacokinetically guided food intervention optimizes abiraterone treatment in mCRPC Meike Lunenburg, Department of Pharmacy OLVG	434. Reinforcement learning for generalized dose optimization Prof Michael Neely, Children's Hospital Los Angeles, University of Southern California	441. Volumetric absorptive microsampling (VAMS) for therapeutic drug monitoring of antiepileptics in children Dr Raffaele Simeoli, Bambino Gesù Children's Hospital	
	421. Real-world experience optimising vancomycin dosing in paediatric ICU using model-informed precision dosing Michael Stokes, SCHN and The University of Sydney	428. Real-world pharmacokinetics of Pembrolizumab in cancer patients: A serial sampling study Dr Jan Gerard Maring, Isala Hospital Zwolle	435. An optimised fluconazole dosing strategy in critically ill patients Luong Vuong, Ku Leuven	442. Volumetric absorptive microsampling (VAMS) to measure steroids in congenital adrenal hyperplasia patients Hanna De Baets, Ghent University	
	422. Real-world free fractions and probability target attainment of Cefoperazone/Sulbactam Yu Ting Huang, Department of Pharmacy, National Taiwan University Hospital	429. Real-world exposure-response analysis of Abiraterone in metastatic castration-resistant prostate cancer Merin Babu, Amrita Vishwa Vidyapeetham, Amrita Institute of medical Sciences and Research Centre	436. Performance evaluation of ceftriaxone population pharmacokinetic models in children Stef Schouwenburg, Erasmus University Medical Center	443. Plasma-To-DBS ratio as transversal conversion factor for DBS-methods: The case of Imatinib Dr Bianca Posocco, Cro Aviano, National Cancer Institute, IRCCS	
	423. Should Beta-lactams and Beta-lactamase-Inhibitors be co-formulated? Insights from Beta-lactam therapeutic drug monitoring Dr Nathalie Grace Sy Chua, Singapore General Hospital	430. Towards model-informed precision dosing and optimal sampling of 5-FU for gastrointestinal cancers Zhiyuan Tan, Leiden University Medical Center	437. Clozapine optimal timing for optimal monitoring (COTTON) Afnan Abdul Roda, Amsterdam UMC	444. Microsampling for adherence monitoring of coronary artery disease drugs: Method development Diana Kretschmer, Saarland University	
	15:00 – 15:45	Closing ceremony Oral and poster award and Young Scientist award presentations Chairs: Prof Jan-Willem Alffenaar, IATDMCT President and Prof Christophe Stove, IATDMCT President elect			

Complementary. Comprehensive. Cutting-edge.

Inspiring confidence in
drug testing and monitoring

Find out more on
diagnostics.roche.com

